Skip to main content
. 2021 Aug 19;11:690816. doi: 10.3389/fonc.2021.690816

Table 5.

Association of clinicopathological variables and individual markers with disease-free survival and overall survival in the second cohort in univariate and multivariate analyses.

Variables a. Univariate analysis b. Multivariate analysis c. Univariate analysis d. Multivariate analysis
HR 95%CI p value HR 95%CI p value HR 95%CI p value HR 95%CI p value
Disease-free survival Overall survival
Sex Woman vs Man 0.819 0.430-1.512 0.5283 0.919 0.395-2.048 0.8320
Location Rectum vs Left colon 1.982 0.976-4.345 0.0588 1.617 0.639-4.603 0.3180
Right colon vs Left colon 1.094 0.417-2.774 0.8505 1.088 0.313-3.613 0.8894
Right colon vs Rectum 1.813 0.850-4.310 0.1278 1.486 0.560-4.632 0.4393
pT pT4 vs pT3 2.279 1.142-4.307 0.0208 1.527 0.714-3.112 0.2662 2.630 1.065-5.986 0.0369 1.936 0.746-4.670 0.1667
Stage III vs II 3.114 1.633-6.334 0.0004 1.991 0.977-4.301 0.0581 4.599 1.847-13.885 0.0007 2.619 0.980-8.321 0.0552
Histological type WDA vs MDA 0.627 0.264-1.492 0.2657 0.787 0.269-2.303 0.6533
Lymphatic invasion Positive vs Negative 4.334 0.944-76.833 0.0620 2.447 0.516-43.777 0.3125
Venous invasion Positive vs Negative 4.855 1.057-86.076 0.0401 4.073 0.838-73.423 0.0904 2.722 0.574-48.690 0.2501
Tumor budding High vs Low 2.291 1.170-4.285 0.0169 1.667 0.825-3.237 0.1497 2.090 0.847-4.752 0.1052
Desmoplastic reaction Immature vs Intermediate 1.520 0.712-3.204 0.2736 1.227 0.451-3.118 0.6754
Immature vs Mature 2.322 1.076-4.976 0.0324 0.993 0.415-2.340 0.9867 3.293 1.092-10.245 0.0348 1.596 0.493-5.305 0.4312
Intermediate vs Mature 1.527 0.733-3.202 0.2558 2.684 1.021-7.793 0.0452 1.895 0.696-5.686 0.2143
α-SMA Positive vs Negative 1.423 0.437-8.736 0.6078 1.580 0.333-28.264 0.6303
CD10 Positive vs Negative 0.657 0.267-1.391 0.2883 0.704 0.295-1.941 0.4698
Podoplamin Positive vs Negative 0.752 0.399-1.496 0.4020 0.564 0.251-1.343 0.1872
FSP1 Positive vs Negative 0.355 0.108-2.185 0.2181 0.296 0.061-5.139 0.3172
FAP Positive vs Negative 0.819 0.425-1.520 0.5323 4.045 0.853-72.358 0.0866
Tenascin-C Positive vs Negative 5.025 2.164-14.621 0.0001 3.973 1.656-11.795 0.0012 4.527 1.559-19.172 0.0036 3.188 1.038-13.882 0.0421
PDGFR-β Positive vs Negative 1.290 0.685-2.566 0.4395 1.416 0.611-3.661 0.4288
ZEB1 Positive vs Negative 0.683 0.248-2.825 0.5463 0.562 0.166-3.510 0.4713
TWIST1 Positive vs Negative 1.067 0.581-1.971 0.8331 1.237 0.553-2.818 0.6028
Ki-67 Positive vs Negative 1.667 0.885-3.316 0.1157 2.952 1.187-8.906 0.0185 2.114 0.834-6.465 0.1191
p53 Positive vs Negative 1.362 0.730-2.663 0.3378 1.255 0.552-3.096 0.5955
MMP7 Positive vs Negative 0.651 0.354-1.199 0.1671 0.823 0.368-1.875 0.6358
β-catenin Positive vs Negative 2.119 1.143-4.084 0.0169 1.502 0.796-2.940 0.2121 1.865 0.830-4.440 0.1323
E-cadherin*
HIF1-α*

WDA, Well-differentiated adenocarcinoma; MUC, mucinous carcinoma; HR, Hazard ratio; 95%CI, 95%confidence interval. *Could not analyze, why all cases were positive expression of the marker.